Sentence examples for durable disease from inspiring English sources

Here, we discuss recent advances and consider future perspectives for producing plants with durable disease resistance.

To engineer plants with increased and durable disease resistance using transgenic technologies we must address two questions.

Targeting T cell recognition on leukemia cells is therefore needed to overcome the problem and ensure safe and durable disease remission.

In several clinical studies, achieving undetectable and durable disease status allowed some patients to discontinue the TKI and enjoy long-term treatment-free remission.

Despite durable disease control in many patients, advanced-stage NTRK fusion-positive cancers eventually become refractory to TRK inhibition; resistance can be mediated by the acquisition of NTRK kinase domain mutations.

Importantly, the project has also revealed a treasure trove of natural resistance in diverse types of tomato that can be used in breeding new, natural, and durable disease resistance in tomato.

Preoperative chemoradiotherapy can result in a long-term and durable disease-free state.

The currently available treatments for OA are effective only on a short term and there is a largely unmet medical need for durable disease-modifying treatments [ 7].

Because patients on ipilimumab may have delayed responses or durable stable disease even after apparent disease progression, these new immune-related response criteria are now evaluated to capture additional response patterns observed with immune therapy in advanced melanoma beyond those described by conventional assessments.

Because patients on anti-CTLA-4 therapy may experience delayed responses or durable stable disease after an initial apparent disease progression (due to tumor T-cell infiltration and inflammation), irRC is now used to better analyze additional responses that would otherwise be classified as progressive disease according to RECIST or WHO criteria.

Clinical endpoints were assessed in a subpopulation of patients who were clinically enriched for EGFR mutations based on Jackman criteria [ 88], i.e. patients with a known EGFR-activating mutation plus patients who had achieved an OR or durable stable disease (SD) for >6 months, followed by systemic disease progression of disease, on continuous gefitinib/erlotinib treatment.